In addition, intravenous injection of AuNP-Apt loaded with epidermal growth factor (EGF) and BIM led to targeted delivery of BIM to xenografts derived from cancer cells overexpressing EGF receptors, with no detectable systemic toxicity. The gene discussed is EGF; the disease is cancer.